Cargando…

2733. Evusheld (AZD7442) Uptake and COVID-19 Outcomes in Solid Organ Transplant Recipients: A Secondary Analysis

BACKGROUND: Evusheld is a pre-exposure prophylaxis for COVID-19. It was recommended for high-risk populations, including solid organ transplant (SOT) recipients, due to their increased risk of severe COVID-19 and suboptimal vaccine response. Evusheld received emergency use authorization (EUA) in 12/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hayek, Haya, Stopczynski, Tess, Khanfar, Asim, Qwaider, Yasmeen Z, Amarin, Justin Z, Stuhlreyer, Madge I, Alsabah, Samar, Frank, Samantha Economos, Johnson, Mackenzie, Perri, Roman, Schlendorf, Kelly, Birdwell, Kelly A, Dee, Kevin C, Dulek, Daniel, Spieker, Andrew J, Chappell, James, Halasa, Natasha B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678392/ http://dx.doi.org/10.1093/ofid/ofad500.2344

Ejemplares similares

1748. Viral and Bacterial Etiology of Acute Gastroenteritis in Children < 5 Years Old at a Major Pediatric Referral Center Before and During the COVID-19 Pandemic
por: Hamdan, Olla, et al.
Publicado: (2023)

1100. Cellular Immunophenotypic Predictors of Influenza Vaccine Immunogenicity in Pediatric Hematopoietic Cell Transplant Recipients
por: Amarin, Justin Z, et al.
Publicado: (2023)

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
por: Levin, Myron J., et al.
Publicado: (2022)

Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring
por: Brady, Tyler, et al.
Publicado: (2022)

1749. Clinical Characteristics and Enteric Viral Detection Among Children with One Vomiting Episode in the Absence of Diarrhea
por: Johnson, Jacob D, et al.
Publicado: (2023)

COVID-19 vaccines protect children of all ages
por: Amarin, Justin Z., et al.
Publicado: (2022)

AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019
por: Levin, Myron J, et al.
Publicado: (2022)

Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants
por: Roe, Tiffany L., et al.
Publicado: (2023)

Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation
por: de Lamballerie, Xavier, et al.
Publicado: (2023)

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
por: Stuver, Robert, et al.
Publicado: (2022)

Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants
por: Tuffy, Kevin M, et al.
Publicado: (2023)

AZD7442 utilization for Pre-Exposure Prophylaxis Against COVID-19 in a French Early Access Program
por: Artaud, C, et al.
Publicado: (2023)

1353. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of COVID-19: Final Analysis of the STORM CHASER Phase 3 Study
por: Levin, Myron J, et al.
Publicado: (2023)

Attitudes of Physicians in Jordan Towards Non-Disclosure of Health Information
por: Borgan, Saif M., et al.
Publicado: (2021)

1143. Prophylactic and Therapeutic Activity of AZD7442 (Tixagevimab/Cilgavimab) in SARS-CoV-2 Hamster Challenge Models
por: Loo, Yueh-Ming, et al.
Publicado: (2022)

LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults
por: Levin, Myron J, et al.
Publicado: (2021)

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial
por: Hobbs, F. D. Richard, et al.
Publicado: (2023)

Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
por: Case, James Brett, et al.
Publicado: (2022)

Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS‐CoV‐2 Infection
por: Bender Ignacio, Rachel A., et al.
Publicado: (2022)

Efficacy of Preexposure Prophylaxis with Monoclonal-Antibody AZD7442 (tixagevimab-cilgavimab) Against Sars-Cov-2 Variants in Patients with CLL
por: Benjamini, Ohad, et al.
Publicado: (2022)

EE572 Cost-Effectiveness of AZD7442 (Tixagevimab and Cilgavimab) for Pre-exposure Prophylaxis Against COVID-19 in the Immunocompromised Population
por: Sutton, K, et al.
Publicado: (2022)

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans
por: Loo, Yueh-Ming, et al.
Publicado: (2022)

Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies
por: Chang, Andres, et al.
Publicado: (2023)

1354. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of COVID-19: 15-Month Final Analysis of the PROVENT Phase 3 Study
por: Levin, Myron J, et al.
Publicado: (2023)

529. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Phase 3 Study
por: Richard Hobbs, F D, et al.
Publicado: (2023)

2733. Association Between Influenza Vaccination Coverage and Ambulatory Antibiotic Prescription Rates in Children in South Carolina
por: Younas, Mariam, et al.
Publicado: (2019)

Multiplex Hybrid Antigen-Capture LC-MRM Quantification in Sera and Nasal Lining Fluid of AZD7442, a SARS-CoV-2-Targeting Antibody Combination
por: Mu, Ruipeng, et al.
Publicado: (2022)

Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults
por: Forte-Soto, Pablo, et al.
Publicado: (2023)

Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients
por: Laracy, Justin C., et al.
Publicado: (2023)

Safety and tolerability of Evusheld in patients with CVID: The Mayo Clinic experience
por: Squire, Jacqueline D., et al.
Publicado: (2023)

Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era
por: Chen, Benjamin, et al.
Publicado: (2023)

SARS-CoV-2 pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) provides protection in inborn errors of immunity with antibody defects: a real-world experience
por: Pulvirenti, Federica, et al.
Publicado: (2023)

Real-World Effectiveness of Tixagevimab and Cilgavimab (Evusheld) in Patients With Hematological Malignancies
por: Ocon, Anthony J., et al.
Publicado: (2022)

394. Consistency of AZD7442 (Cilgavimab/Tixagevimab) Pharmacokinetics Across Prophylaxis and Treatment and Adult and Pediatric Participants: Application of Population Pharmacokinetics to Enable Rapid Decision-Making During the COVID-19 Pandemic
por: Clegg, Lindsay E, et al.
Publicado: (2023)

1754. Parainfluenza Virus Co-detection With Respiratory Syncytial Virus or Influenza is Associated with Higher Odds of Hospitalization in Children < 2 Years Old, New Vaccine Surveillance Network (NVSN), 2016–2020
por: Qwaider, Yasmeen Z, et al.
Publicado: (2023)

Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients
por: Aqeel, Faten, et al.
Publicado: (2022)

P1574: EFFICACY AND SAFETY OF TIXAGEVIMAB AND CILGAVIMAB (EVUSHELD) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
por: Aleshina (Gavrilina), Olga, et al.
Publicado: (2023)

BVT.2733, a Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor, Attenuates Obesity and Inflammation in Diet-Induced Obese Mice
por: Wang, Long, et al.
Publicado: (2012)

Tixagevimab and Cilgavimab (Evusheld – AstraZeneca) efficacy in preventing COVID infection in immunocompromised patients
por: Miot, Christelle, et al.
Publicado: (2023)

(1200) Evusheld Protects Against SARS-CoV-2 in Lung Transplant Recipients
por: Eck, D., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dfjct8ejdtvcealqviufsd1ku6